A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

Abstract Background According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas frail patients are recommended gemcitabine (Gem) monotherapy. Randomized controlled trials in colorectal cancer and a post-hoc analys...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-06-01
Edice:	BMC Cancer
Témata:	Chemotherapy dose Comorbidity Frail Older patients Pancreatic cancer Randomized study
On-line přístup:	https://doi.org/10.1186/s12885-023-11035-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!